Jennifer R Keeffe
Overview
Explore the profile of Jennifer R Keeffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang E, Cohen A, Caldera L, Keeffe J, Rorick A, Adia Y, et al.
Cell
. 2025 Jan;
188(4):1036-1050.e11.
PMID: 39855201
Nanoparticle vaccines displaying combinations of SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs) could protect against SARS-CoV-2 variants and spillover of zoonotic sarbecoviruses into humans. Using a computational approach, we designed variants...
2.
Gristick H, Hartweger H, Nishimura Y, Gavor E, Nagashima K, Koranda N, et al.
bioRxiv
. 2025 Jan;
PMID: 39829910
A primary goal in the development of an AIDS vaccine is the elicitation of broadly neutralizing antibodies (bNAbs) that protect against diverse HIV-1 strains. To this aim, germline-targeting immunogens have...
3.
Fan C, Keeffe J, Malecek K, Cohen A, West Jr A, West A, et al.
bioRxiv
. 2025 Jan;
PMID: 39803445
Therapeutic monoclonal antibodies (mAbs) against SARS-CoV-2 become obsolete as spike substitutions reduce antibody binding. To induce antibodies against conserved receptor-binding domain (RBD) regions for protection against SARS-CoV-2 variants of concern...
4.
DeLaitsch A, Keeffe J, Gristick H, Lee J, Ding W, Liu W, et al.
NPJ Vaccines
. 2024 Dec;
9(1):240.
PMID: 39638818
Eliciting broadly neutralizing antibodies that protect against diverse HIV-1 strains is a primary goal of AIDS vaccine research. We characterized Ab1456 and Ab1271, two heterologously-neutralizing antibodies elicited in non-human primates...
5.
Cohen A, Keeffe J, Schiepers A, Dross S, Greaney A, Rorick A, et al.
Cell
. 2024 Aug;
187(20):5554-5571.e19.
PMID: 39197450
Immunization with mosaic-8b (nanoparticles presenting 8 SARS-like betacoronavirus [sarbecovirus] receptor-binding domains [RBDs]) elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses. To investigate original antigenic...
6.
Cervantes Rincon T, Kapoor T, Keeffe J, Simonelli L, Hoffmann H, Agudelo M, et al.
Cell Rep
. 2024 May;
43(6):114298.
PMID: 38819991
Flaviviruses such as dengue virus (DENV), Zika virus (ZIKV), and yellow fever virus (YFV) are spread by mosquitoes and cause human disease and mortality in tropical areas. In contrast, Powassan...
7.
Hills R, Tan T, Cohen A, Keeffe J, Keeble A, Gnanapragasam P, et al.
Nat Nanotechnol
. 2024 May;
19(8):1216-1223.
PMID: 38710880
Defending against future pandemics requires vaccine platforms that protect across a range of related pathogens. Nanoscale patterning can be used to address this issue. Here, we produce quartets of linked...
8.
Wang E, Cohen A, Caldera L, Keeffe J, Rorick A, Aida Y, et al.
bioRxiv
. 2024 Mar;
PMID: 38464322
1Using computational methods, we designed 60-mer nanoparticles displaying SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs) by () creating RBD sequences with 6 mutations in the SARS-COV-2 WA1 RBD that were predicted...
9.
Cohen A, Keeffe J, Schiepers A, Dross S, Greaney A, Rorick A, et al.
bioRxiv
. 2024 Feb;
PMID: 38370696
Immunization with mosaic-8b [60-mer nanoparticles presenting 8 SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs)] elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses. To investigate original...
10.
Hills R, Tan T, Cohen A, Keeffe J, Keeble A, Gnanapragasam P, et al.
bioRxiv
. 2023 Mar;
PMID: 36865256
Defending against future pandemics may require vaccine platforms that protect across a range of related pathogens. The presentation of multiple receptor-binding domains (RBDs) from evolutionarily-related viruses on a nanoparticle scaffold...